Investigating a new form of a protein that may cause cancer treatment resistance
Novel Topoisomerase II alpha isoform as a drug resistance determinant
This study is looking at a special protein that helps cancer drugs work better, and it wants to find out how a shorter version of this protein makes leukemia cells resistant to a common chemotherapy drug called etoposide, so that doctors can find new ways to help patients who aren't responding to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10531227 on NIH RePORTER |
What this research studies
This research focuses on a specific protein called DNA Topoisomerase IIα (TOP2α), which is crucial for the effectiveness of many cancer drugs. The study aims to understand how a novel, shorter version of this protein, known as TOP2α/90, contributes to resistance against the chemotherapy drug etoposide in leukemia cells. By analyzing patient samples and conducting laboratory experiments, the researchers hope to uncover the mechanisms behind this resistance and identify potential ways to overcome it. This could lead to improved treatment strategies for patients who do not respond to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with leukemia who have experienced resistance to chemotherapy treatments.
Not a fit: Patients with cancers that do not involve the TOP2α protein or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new approaches for overcoming drug resistance in cancer treatment, potentially improving outcomes for patients.
How similar studies have performed: Previous research has shown that targeting alternative protein isoforms can be effective in addressing drug resistance, suggesting that this approach may yield promising results.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Yalowich, Jack C. — Ohio State University
- Study coordinator: Yalowich, Jack C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.